Targeting EZH1/2: tackling epigenetic resistance advances cancer therapy

Ram Abou Zaki; Assam El-Osta

doi:10.1002/mco2.70022

MedComm ›› 2025, Vol. 6 ›› Issue (1) : e70022 DOI: 10.1002/mco2.70022

HIGHLIGHT

Targeting EZH1/2: tackling epigenetic resistance advances cancer therapy

Ram Abou Zaki ¹^,²
, Assam El-Osta ¹^,³^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Ram Abou Zaki, Assam El-Osta. Targeting EZH1/2: tackling epigenetic resistance advances cancer therapy. MedComm, 2025, 6(1): e70022 DOI:10.1002/mco2.70022

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Yamagishi M, Kuze Y, Kobayashi S, et al. Mechanisms of action and resistance in histone methylation-targeted therapy. Nature. 2024; 627(8002): 221-228.

[2]	El Hajj H, Tsukasaki K, Cheminant M, Bazarbachi A, Watanabe T, Hermine O. Novel treatments of adult T cell leukemia lymphoma. Front Microbiol. 2020; 11: 1062.

[3]	Ito S, Iwanaga M, Nosaka K, et al. Epidemiology of adult T-cell leukemia-lymphoma in Japan: an updated analysis, 2012–2013. Cancer Sci. 2021; 112(10): 4346-4354.

[4]	Straining R, Eighmy W. Tazemetostat: eZH2 Inhibitor. J Adv Pract Oncol. 2022; 13(2): 158-163.

[5]	Liu Y, Yang Q. The roles of EZH2 in cancer and its inhibitors. Med Oncol. 2023; 40(6): 167.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.